In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

In PAH, 5-year mortality is similar with and without obesity, even though patients with obesity have more comorbidities and worse functional capacity.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America ...

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts ...

Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...